Veeva Systems
VEEV
$299.28
-0.75%
Veeva Systems is the dominant vertical cloud software provider for the global life sciences industry, delivering purpose-built applications — most notably Veeva CRM for commercial and sales teams and the Veeva Vault suite for regulatory, quality, clinical, and safety content management — to customers ranging from emerging biotechs to the largest pharmaceutical manufacturers. Its competitive identity rests on deep domain expertise and a best-of-breed, industry-specific architecture that has displaced rigid, heavily customized legacy ERP and horizontal platforms, giving Veeva a moat-like position within a niche it largely created. The current investor narrative centers on the Vault CRM migration cycle as large pharma customers transition off the Salesforce-backed platform, compounded by raised FY27 guidance and accelerating AI-related momentum across the Vault and CRM franchises following a strong Q2 beat. That optimism is tempered by a persistent bear argument around competitive pressure, market saturation in the core commercial cloud, and a valuation that already discounts years of durable double-digit growth.…
VEEV
Veeva Systems
$299.28
Related headlines
Investment Opinion: Should I buy VEEV Today?
Rating: Hold (accumulate on weakness). Veeva is a best-in-class vertical software franchise with 17.6% revenue growth, 75.0% gross margins, 29.47% net margins, $1.64 billion of trailing free cash flow, and a near-debt-free balance sheet (D/E 0.0133), but after an 89.81% six-month run the shares sit at $301.53 against a $326.41 average analyst target — only ~8.3% implied upside — so the risk/reward is balanced rather than compelling at current levels. The consensus 'buy' rating (20 Buy / 8 Hold / 1 Sell, mean 1.93) supports owning the business; the thin target gap argues for patience on entry.
Supporting evidence is strong on every fundamental axis: the PE has compressed from 57.76x in Q2 FY26 to 36.74x trailing and 29.38x forward, PS has fallen from 58.75x to 10.44x, and the PEG of 1.42 on a 75.5% gross-margin franchise is reasonable rather than egregious. Revenue has climbed sequentially from $811.24 million (Q3 FY26) to $835.95 million, $882.95 million, and $927.96 million in Q2 FY27, while net margin expanded to 29.47% from 25.39% a year ago and EBITDA margin reached 38.84%. Free cash flow of $1.64 billion funds $245.73 million of Q2 buybacks and bolt-on M&A from internal generation, and the $400 high target versus the $180 low target frames a 120%+ dispersion that reflects genuine debate over Vault CRM migration durability and AI monetization.
Three risks could invalidate the thesis: (1) large-pharma Vault CRM conversions slipping or competitive share loss, which the $180 low target explicitly bakes in as roughly -40% downside; (2) multiple compression if high-teens growth decelerates, given the 29.38x forward PE leaves little cushion for an earnings miss; and (3) the stock's demonstrated capacity for violent drawdowns — a -49.37% max drawdown in the past year despite a 0.881 beta. This Hold would upgrade to Buy on a pullback toward the $280–$285 consolidation zone (implying ~12–15% upside to the average target) or on evidence of accelerating subscription growth from Vault CRM conversions; it would downgrade to Sell if revenue growth decelerates below 12% or if a major pharma customer publicly reverses a Vault CRM commitment. Verdict: fairly valued relative to history (near multi-year low multiples) but fully valued relative to near-term consensus targets — a high-quality business at a fair, not discounted, price.
Sign up to view all
VEEV 12-Month Price Forecast
Veeva is a high-quality, cash-generative vertical software franchise trading at a fair price after a dramatic re-rating — the forward PE of 29.38x and PEG of 1.42 are reasonable for 17.6% growth and 75% gross margins, but the stock has already caught up to the $326.41 consensus target, leaving limited near-term upside. The bull and bear cases hinge on a single variable: whether the Vault CRM migration cycle converts into accelerating subscription growth and AI monetization, which would justify a re-rating toward the $400 high target, or whether large-pharma conversions slip and competitive pressure materializes, opening the path toward the $180 low target. Analyst sentiment is constructive (20 Buy / 8 Hold / 1 Sell) but recent institutional actions were reaffirmations rather than upgrades, indicating stable conviction without fresh catalysts. I would upgrade to bullish on a pullback toward the $280–$285 consolidation zone or on evidence of accelerating subscription growth; I would downgrade to bearish if revenue growth decelerates below 12% or a major pharma customer reverses a Vault CRM commitment.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $326.41 and implied upside of +9.1% versus the current price.
Average Target
$326.41
29 analysts
Implied Upside
+9.1%
vs. current price
Analyst Count
29
covering this stock
Price Range
$180 - $400
Analyst target range
Coverage is broad and constructive: 27 analysts follow Veeva, with 20 Buy ratings, 8 Holds, and 1 Sell, yielding a consensus recommendation of "buy" (mean score 1.93 on a 1-to-5 scale where lower is more bullish). The average target price of $326.41 implies roughly +8.3% upside from the current $301.53, a modest gap that suggests the stock has largely caught up to Street expectations after its 89.81% six-month run. The bullish tilt in ratings is clear, but the thin implied upside signals that consensus sees the shares as fairly valued near current levels rather than deeply undervalued.
The target range is wide — from a low of $180.00 to a high of $400.00 — a spread of more than 120% that signals genuine disagreement about the durability of the Vault CRM migration and AI monetization. The $400 high target likely assumes accelerating subscription growth, successful large-pharma conversions, and multiple expansion back toward historical norms, while the $180 low bakes in competitive share loss and margin compression. Recent institutional actions are overwhelmingly reaffirmations rather than upgrades — Wells Fargo, BTIG, Truist, RBC, Jefferies, Needham, and Barclays all maintained Buy/Overweight/Outperform ratings in November, with UBS, Evercore, and Canaccord holding Neutral — indicating stable conviction but a lack of fresh catalysts to drive estimate revisions higher.
Bulls vs Bears: VEEV Investment Factors
The bull case rests on stronger, more quantifiable evidence: 17.6% revenue growth, 75.0% gross margins, 29.47% net margins, $1.64 billion of trailing free cash flow, a near-debt-free balance sheet (D/E 0.0133), and a valuation that has compressed to 29.38x forward earnings from over 50x a year ago. The bear case is largely about price and positioning rather than fundamentals — only ~8.3% upside to the $326.41 average target after an 89.81% six-month run, a -49.37% max drawdown in the past year, and a 120%+ spread in analyst targets. On balance the bulls have the better evidence, but the margin of victory is narrow because the stock has already caught up to Street expectations. The single most important tension is whether the Vault CRM migration cycle converts into accelerating subscription growth and AI monetization — if it does, the compressed multiple re-rates higher toward the $400 high target; if large-pharma conversions slip or competitive share loss materializes, the $180 low target becomes the reference point and the recent run unwinds.
Bullish
- Vault CRM migration fuels durable growth: Q2 FY27 revenue of $927.96 million grew 17.6% year-over-year, extending a sequential cadence from $811.24 million in Q3 FY26 to $835.95 million, $882.95 million, and now $927.96 million. The raised FY27 outlook tied to large-pharma Vault CRM conversions and AI momentum suggests this high-teens expansion can persist as customers migrate off the Salesforce-backed platform.
- Fortress balance sheet with prodigious cash flow: Debt-to-equity is just 0.0133 and the current ratio is 4.89, with $1.81 billion of cash at quarter-end. Trailing-twelve-month free cash flow of $1.64 billion against a $33.37 billion market cap funds $245.73 million of Q2 buybacks and bolt-on acquisitions entirely from internal generation, eliminating financing risk.
- Best-in-class margins with operating leverage: Gross margin held at 75.0% ($695.95 million on $927.96 million of revenue) while net margin expanded to 29.47% from 25.39% a year ago, and EBITDA margin reached 38.84%. R&D ($222.92 million) and sales and marketing ($126.70 million) are growing slower than revenue, confirming genuine operating leverage rather than one-off gains.
- Valuation near multi-year lows: The PE ratio has compressed from 57.76x in Q2 FY26 and 50.56x in Q3 FY26 to 36.74x trailing and 29.38x forward, while PS fell from 58.75x to 10.44x. A PEG of 1.42 on a franchise with 75% gross margins and accelerating AI/CRM catalysts argues the premium is reasonable rather than egregious.
Bearish
- Thin implied upside after 89.81% run: The stock has surged 89.81% over six months and 37.38% year-to-date versus a 10.62% SPY gain, leaving only ~8.3% upside to the $326.41 average target. At $301.53 the shares sit at roughly 86% of the 52-week range (high $325.99), meaning consensus sees them as fairly valued rather than undervalued.
- Severe drawdown history despite low beta: A max drawdown of -49.37% over the past year shows the stock round-tripped violently from a $148.05 low, and the 1-year return of just +3.37% masks that damage. Beta of 0.881 did not insulate shareholders from a near-halving, undercutting the defensive narrative for this high-multiple name.
- Growth is steady, not accelerating: The 17.6% year-over-year revenue growth is consistent with a maturing category leader rather than a re-accelerating story, and the commercial cloud segment remains the revenue backbone. With subscription services at $347.39 million dwarfing professional services at $59.74 million, the model is high-visibility but offers limited upside surprise potential.
- Competitive pressure and saturation debate: Zacks' October note explicitly cites competitive pressures and market saturation in justifying a Hold despite the Q2 beat and raised guidance. The $180 low analyst target bakes in competitive share loss and margin compression, a 40% downside from current levels that reflects genuine disagreement about the moat.
VEEV Technical Analysis
Veeva is in a powerful, sustained uptrend that has carried shares from a 52-week low of $148.05 to a current price of $301.53, a move that places the stock at roughly 86% of its 52-week range (high of $325.99). The 1-year price change of just +3.37% masks the violence of the round trip — a max drawdown of -49.37% followed by a near-vertical recovery — meaning current positioning reflects momentum near the upper end of the band rather than a stock that has simply drifted higher. Trading this close to the highs signals strong trend conviction but also raises the risk of overextension and profit-taking, particularly given the stock is up 37.38% year-to-date versus a 10.62% gain for SPY.
Short-term momentum is decisively positive and has been accelerating: shares are up 23.70% over three months and 89.81% over six months, with a modest +1.41% gain in the last month that represents consolidation rather than reversal after the October peak above $323. Relative strength confirms the acceleration — VEEV has outperformed SPY by 26.53 percentage points over three months and a striking 87.68 points over six months, though the 1-year relative strength of -8.90 points shows the stock is still repairing damage from its earlier drawdown. The 1-month stall against the 6-month surge looks like healthy digestion of gains rather than distribution, but the divergence between the +3.37% 1-year return and the +89.81% 6-month return is a reminder that much of the move is recent and untested.
Key technical resistance sits at the 52-week high of $325.99, roughly 8% above the current $301.53; a clean breakout there would confirm the uptrend and likely invite momentum buyers, while failure could set up a double-top. Support is anchored by the 52-week low of $148.05, with intermediate support likely in the $280–$285 zone where the stock consolidated in September and early October. With a beta of 0.881, Veeva is roughly 12% less volatile than the broad market, which is unusually defensive for a high-multiple software name and argues for somewhat larger position sizing on a risk-adjusted basis — though the -49.37% max drawdown shows that low beta has not insulated shareholders from severe drawdowns.
Beta
0.88
0.88x market volatility
Max Drawdown
-49.4%
Largest decline past year
52-Week Range
$148-$326
Price range past year
Annual Return
+2.0%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | -3.0% |
| 3m | +23.3% | -3.6% |
| 6m | +81.4% | -0.2% |
| 1y | +2.0% | +10.1% |
| ytd | +36.4% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue is growing at a healthy and stable clip: Q2 FY27 revenue of $927.96 million rose 17.6% year-over-year, extending a multi-quarter cadence that has climbed sequentially from $811.24 million in Q3 FY26 to $835.95 million in Q4, $882.95 million in Q1 FY27, and now $927.96 million. The commercial cloud segment remains the revenue backbone, with subscription services at $347.39 million dwarfing professional services at $59.74 million, underscoring the recurring, high-visibility nature of the model. Growth is steady rather than accelerating, consistent with a maturing category leader, but the raised FY27 outlook tied to Vault CRM adoption and AI momentum suggests the migration cycle can sustain high-teens expansion.
Profitability is robust and improving: Q2 net income of $273.43 million produced a 29.47% net margin, up from 25.39% in the year-ago quarter, while gross margin held at a software-typical 75.0% ($695.95 million on $927.96 million of revenue). Operating income of $275.02 million equates to a 29.64% operating margin, and EBITDA of $360.40 million represents a 38.84% EBITDA margin — a profile that reflects both pricing power and operating leverage as R&D ($222.92 million) and sales and marketing ($126.70 million) grow slower than revenue. The margin trajectory across the last four quarters (net margin 29.2% → 29.6% → 29.5% → 29.5%) is remarkably stable, signaling disciplined cost control rather than one-off gains.
The balance sheet is fortress-like: debt-to-equity of just 0.0133 and a current ratio of 4.89 mean the company is effectively debt-free with ample liquidity, and $1.81 billion of cash at the end of Q2 provides a large cushion. Free cash flow is prodigious — $1.64 billion on a trailing-twelve-month basis — against a $33.37 billion market cap, and ROE of 12.60% and ROA of 7.58% are solid for a company that carries excess cash and investments. Veeva funds growth, buybacks ($245.73 million repurchased in Q2), and small acquisitions entirely from internal cash generation, eliminating financing risk and giving management unusual strategic flexibility.
Quarterly Revenue
$927963000.0B
2026-07
Revenue YoY Growth
+17.6%
YoY Comparison
Gross Margin
75.0%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Because Veeva is solidly profitable (Q2 net income of $273.43 million), the PE ratio is the appropriate primary metric. The stock trades at 36.74x trailing earnings but only 29.38x forward earnings, and the roughly 20% compression between the two implies the market expects meaningful EPS growth — consistent with consensus FY estimates of about $14.55 per share. The PEG ratio of 1.42 suggests investors are paying a modest premium to growth, while the 10.44x PS ratio and 12.07x EV/Sales reflect the premium multiple typical of high-margin vertical software.
On a peer basis, Veeva's 36.74x trailing PE and 10.44x PS sit at the high end of the application-software universe, though precise industry averages are not provided in the data. The 25.74x EV/EBITDA and 4.63x price-to-book are more moderate, and the 75.5% gross margin and 28.4% net margin justify a premium versus lower-margin SaaS peers. The key question is whether a ~29x forward multiple is warranted by high-teens revenue growth and best-in-class margins — the PEG of 1.42 argues the premium is reasonable rather than egregious, but it leaves little room for execution missteps.
Historically, Veeva's valuation has compressed dramatically: the PE ratio stood at 57.76x in Q2 FY26 and 50.56x in Q3 FY26 before falling to 36.74x today, while the PS ratio has fallen from 58.75x to 10.44x. That compression reflects both multiple derating and rapid earnings growth, placing the stock near the low end of its own multi-year valuation band. Near-historical-low multiples on a franchise with stable 75% gross margins and accelerating AI/CRM catalysts can signal a value opportunity — but the market's willingness to pay less for the same growth also reflects lingering concerns about saturation and competition that investors should weigh.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~73x
vs. Industry Avg
31.1x
Industry PE ~31.1x*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are modest but not absent. The company is effectively debt-free (debt-to-equity 0.0133) with a 4.89 current ratio and $1.81 billion of cash, so solvency is not a concern; the real risk is that valuation depends on continued high-teens growth. Revenue growth of 17.6% year-over-year is steady rather than accelerating, and the commercial cloud segment remains the revenue backbone, creating concentration in a maturing category. Margins are stable (net margin 29.2% → 29.6% → 29.5% → 29.5% across four quarters) but any deceleration in subscription services ($347.39 million) would pressure the 29.38x forward multiple quickly, and the trailing PE of 36.74x leaves little cushion for an earnings miss.
Market and competitive risks center on valuation compression and saturation. At 10.44x PS and 12.07x EV/Sales, Veeva trades at the high end of the application-software universe, and the PEG of 1.42 leaves little room for execution missteps. Zacks' October note flags competitive pressures and market saturation as reasons to stay on the sidelines despite the Q2 beat, and the $180 low analyst target explicitly bakes in competitive share loss and margin compression. With a beta of 0.881 the stock is roughly 12% less volatile than the market, but that did not prevent a -49.37% max drawdown, and the 1-year relative strength of -8.90 points versus SPY shows the shares are still repairing damage from that episode.
In a worst-case scenario, large-pharma Vault CRM conversions slip, AI monetization disappoints, and a competitive win by a horizontal platform forces pricing concessions — compressing both growth and margins simultaneously. That chain would likely take the stock back toward the $180 analyst low, a decline of roughly -40% from the current $301.53, and in a broader growth de-rating it could retest the $148.05 52-week low, a loss of about -51%. Given the -49.37% max drawdown already experienced in the past year, a repeat of that magnitude is a realistic, not theoretical, downside for investors entering near the top of the 52-week range.
FAQ
Ranked by severity: first, company-specific execution risk around the Vault CRM migration — if large-pharma conversions slip or a top-20 customer reverses a commitment, the $180 low analyst target implies roughly -40% downside from $301.53. Second, valuation/multiple risk: at 10.44x PS and 29.38x forward PE, any deceleration below the current 17.6% revenue growth would likely trigger estimate cuts and multiple compression, and the -49.37% max drawdown in the past year shows how violently this stock can de-rate. Third, competitive risk: Zacks' October note explicitly cites competitive pressures and market saturation in justifying a Hold, and a horizontal platform such as Salesforce or a hyperscaler winning life-sciences CRM share with aggressive pricing would pressure both growth and margins. Fourth, financial risk is the least severe — debt-to-equity of 0.0133, a 4.89 current ratio, and $1.81 billion of cash mean solvency is not a concern, though the 36.74x trailing PE still leaves the stock sensitive to any earnings volatility.
The 12-month outlook is split into three scenarios: a base case at 55% probability with a $315–$340 range (anchored on the $326.41 average target), a bull case at 25% probability with a $360–$400 range (anchored on the $400 high target), and a bear case at 20% probability with a $180–$240 range (anchored on the $180 low target). The base case is most likely and assumes revenue growth holds in the 16–18% band, net margin stays near 29–30%, forward EPS lands near $14.55 on $5.86 billion of revenue, and the forward PE holds near 29x as the stock consolidates after its 89.81% six-month run. The bull case requires Vault CRM conversions to convert on schedule, AI attach rates to accelerate, and FY27 guidance to be raised again, driving the multiple toward the mid-30s. The bear case requires conversion slippage, AI disappointment, and pricing concessions that compress growth and margins together, taking the multiple toward the low-20s.
VEEV looks fairly valued relative to its own history but premium relative to the broad application-software universe. The trailing PE of 36.74x and forward PE of 29.38x compare with 57.76x in Q2 FY26 and 50.56x in Q3 FY26, and the PS ratio has fallen from 58.75x to 10.44x, placing the stock near the low end of its multi-year valuation band. The PEG of 1.42 and EV/EBITDA of 25.74x are moderate for a franchise with 75.5% gross margins and 28.4% net margins, while the 4.63x price-to-book reflects an asset-light model. What the market is paying for is continued high-teens growth plus successful Vault CRM conversions and AI monetization — the 29.38x forward multiple on consensus EPS of $14.55 leaves little cushion for an earnings miss. In short, the stock is not overvalued on its own history, but it is fully valued against the $326.41 consensus target, meaning the market already discounts the base case.
From a risk/reward standpoint VEEV is a reasonable but not compelling buy at $301.53: the average analyst target of $326.41 implies only about +8.3% upside, while the $180 low target implies roughly -40% downside, so the asymmetry is modestly unfavorable at current levels despite 20 of 27 analysts rating it Buy (mean 1.93). The fundamental case is strong — 17.6% revenue growth, 75.0% gross margin, 29.47% net margin, $1.64 billion of trailing free cash flow, and a 0.0133 debt-to-equity ratio — and the 29.38x forward PE is near multi-year lows versus 57.76x a year ago. The biggest downside risk is a Vault CRM conversion slip or competitive share loss that would compress both growth and the multiple simultaneously, a scenario the -49.37% max drawdown shows is realistic. It is a good buy for long-horizon investors who can add on weakness toward the $280–$285 consolidation zone, and a less attractive entry for short-term traders chasing a stock already up 89.81% in six months.
VEEV is better suited to long-term holding than short-term trading. The business is a mature-but-growing category leader with 17.6% revenue growth, 75.0% gross margins, $1.64 billion of trailing free cash flow, and a fortress balance sheet (debt-to-equity 0.0133, current ratio 4.89), which supports multi-year compounding, but the stock's 0.881 beta did not prevent a -49.37% max drawdown and its 1-year return of just +3.37% masks an 89.81% six-month surge — a volatility profile that punishes short-term timing. There is no dividend (0% yield, payout ratio 0), so total return depends entirely on price appreciation and earnings growth, reinforcing a multi-year horizon. Earnings visibility is high given the recurring subscription model ($347.39 million of subscription services versus $59.74 million of professional services), which supports holding through quarterly noise. A suggested minimum holding period is 2–3 years, with position sizing that accounts for the demonstrated capacity for a near-50% drawdown and staged entry on pullbacks toward the $280–$285 zone.

